Home・Lista de Ações・Merck & Co Inc.

Merck & Co Inc.

Fechado

SetorSaúde

130.3 -0.41

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

129.69

Máximo

132.76

Indicadores-chave
By Trading Economics
Rendimento	-7.2B -4.2B
Vendas	-114M 16B
P/E Médio do Setor	35.992 68.51
EPS	-1.28
Rendimento de Dividendos	2.52
Margem de lucro	-26.053
Funcionários	73,000
EBITDA	-6.4B -2B

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+6.13% upside

Dividendos
By Acuity
Rendimento de Dividendos Médio do Setor	2.52% 2.29%
Próximos Ganhos	29 de out. de 2026
Próxima data de dividendos	7 de out. de 2026
Próxima data de ex-dividendo	15 de set. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	35B 307B
Abertura anterior	130.71
Fecho anterior	130.3

Sentimento de Notícias

By Acuity

52%

48%

247 / 340 Ranking em Healthcare

Merck & Co Inc. Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de ago. de 2026, 19:36 UTC

Social Media

News

Merck & Co Inc disclosed a $3.76 million stake in Evaxion Biotech, boosting shares higher amid positive sentiment and strong options trading ahead of earnings.

7 de ago. de 2026, 22:06 UTC

Merck & Co Inc. shares were roughly flat in after-market hours. This stability aligns with broader positive sentiment on Wall Street amid easing interest rate concerns.

6 de ago. de 2026, 23:01 UTC

Event

Merck & Co Inc shares are trading lower in after-market hours following the FDA's acceptance of a supplemental application for ENFLONSIA™.

5 de ago. de 2026, 19:43 UTC

News

Social Media

Merck & Co. received Health Canada approval for Keytruda, yet shares are lower amid mixed market sentiment following disappointing ADP employment data.

4 de ago. de 2026, 23:26 UTC

News

Merck & Co Inc reported a Q2 net loss of $1.3 billion. Shares are higher in after-market hours amid broader market gains from oil supply negotiations.

3 de ago. de 2026, 20:03 UTC

News

Social Media

Merck & Co Inc shares are lower as the company prepares for Q2 earnings on August 4, despite reporting $16.29 billion in last quarter revenues.

31 de jul. de 2026, 23:16 UTC

Merck & Co Inc shares are higher in after-market hours, maintaining a position near the upper end of their one-month range amid varied broader market performance.

30 de jul. de 2026, 20:09 UTC

Merck & Co Inc shares are declining, with no specific news identified. Broader market volatility is influenced by mixed economic signals and jobless claims.

29 de jul. de 2026, 23:41 UTC

Merck & Co Inc shares are lower in after-market hours, driven by weakness in the Pharmaceuticals sub-sector. The stock remains above its 20-day moving average.

28 de jul. de 2026, 23:01 UTC

Merck & Co Inc shares are higher in after-market hours, maintaining stability above the 20-day moving average and near the upper end of their one-month range.

27 de jul. de 2026, 20:06 UTC

Social Media

Merck & Co Inc shares are lower, testing the $132 level amid broader market declines and declining oil prices impacting Treasury yields ahead of the Fed meeting.

24 de jul. de 2026, 18:56 UTC

News

Social Media

Merck & Co Inc. announced a strategy to enhance access to its HIV prevention drug Alimatravir across 129 countries, boosting shares during Friday's session.

22 de jul. de 2026, 19:46 UTC

Social Media

Merck & Co Inc shares are higher, supported by strong contract performance valued at $1,000. The stock remains near its one-month high amid broader market challenges.

21 de jul. de 2026, 19:56 UTC

News

Social Media

Merck & Co. Inc. shares are rising following positive Phase 3 trial results for its once-weekly oral HIV treatment regimen, islatravir and lenacapavir.

20 de jul. de 2026, 20:02 UTC

Social Media

Merck & Co. shares are lower as the pharmaceutical sector faces pressure. The company plans to price Lipfendra at $10.50 per day.

Comparação entre Pares

Variação de preço

Merck & Co Inc. Previsão

Preço-alvo

By TipRanks

6.13% parte superior

Previsão para 12 meses

Média 138.94 USD 6.13%

Máximo 155 USD

Mínimo 100 USD

Com base em 17 analistas de Wall Street que oferecem metas de preço de 12 meses para Merck & Co Inc. - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

17 ratings

Comprar

Manter

Vender

Com base em 17 analistas que deram avaliações de ações para Merck & Co Inc. - Dist nos últimos 3 meses.

Sentimento

By Acuity

247 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.